The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial https://www.medscape.com/viewarticle/prevent-calculator-best-determining-cvd-risk-insights-post-2025a1000svo <ul> <li>PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037</li> <li>SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939</li> </ul> II GLP-1 Mechanism of Action in CV Disease <ul> <li>Analysis of SELECT Trial 10.1016/S0140-6736(25)01375-3 External Link</li> <li>SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563</li> </ul> III Statins and CAD Phenotype on CTA and Outcomes <ul> <li>Interactions Between Statin Use, CAD Phenotypes on CTA  https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018</li> <li>Statin Use for Primary Prevention of CVD https://jamanetwork.com/journals/jama/fullarticle/2795522</li> </ul> IV HHF Endpoints in Heart Failure Trials <ul> <li>The Problem with Hospitalization Endpoints in HF Trials https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070</li> </ul> You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Oct 24 2025 This Week in Cardiology

This Week in Cardiology

AI Chapters

AI Insights

Reviews